Prolonged Survival with Imatinib Mesylate Combined with Chemotherapy and Allogeneic Stem Cell Transplantation in de novo Ph+ Acute Myeloid Leukemia

Sun, Jie; Wang, Zhen; Luo, Yi; Tan, Yamin; Allan, David S.; Huang, He

doi:10.1159/000334109

Cited by 14 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Some authors have shown that Ph+ AML patients must be treated by TKIs and allo-HSCT if they are fit and have molecular or additional karyotype abnormalities resulting in a poor outcome. 12,21 Eight of 21 patients (38%) received allo-HSCT and TKIs, with Table 3). Among them, two had relapsed.…”

Section: Discussionmentioning

confidence: 99%

Rare but authentic Philadelphia-positive acute myeloblastic leukemia

Réboursière

Chantepie

Gac

et al. 2015

Hematology/Oncology and Stem Cell Therapy

View full text Add to dashboard Cite

The Philadelphia chromosome (Ph+), corresponding to translocation t(9;22), is found in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia. Several cases of Ph+ acute myeloid leukemia (AML) have been reported in the literature. A retrospective study of Ph+ AML between 2001 and 2012 was conducted through a review of the literature. Among 400 AML patients, two cases of Ph+ AML (0.5%) were identified and treated with conventional chemotherapy with or without tyrosine kinase inhibitors (TKIs), followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). One patient had a complex karyotype including 7 monosomy (-7) and p190 BCR-ABL fusion transcript. Both patients remain in complete molecular remission. To date, 21 Ph+ AML cases treated with TKIs have been described in the literature with a median overall survival of 18months. One-third of the patients had additional karyotypic abnormalities, and 14% had -7. Molecular analysis showed 59% p210 and 41% p190 fusion protein. Relapse rate was observed in 38% of patients with p190 compared to 10% in patients with p210. Allo-HSCT was performed in eight patients; two relapsed (25%). Cytogenetic (-7) and molecular features help to distinguish Ph+ AML from CML. Survival improved with TKIs, particularly in association with conventional chemotherapy and allo-HSCT. Further studies of Ph+ AML patients are needed to better define this entity, its prognostic value, and therapeutic strategy.

show abstract

Section: Discussionmentioning

confidence: 99%

Rare but authentic Philadelphia-positive acute myeloblastic leukemia

Réboursière

Chantepie

Gac

et al. 2015

Hematology/Oncology and Stem Cell Therapy

View full text Add to dashboard Cite

show abstract

“…Sun et al (17) reported 2 patients with Ph + AML, who were treated with IM and daunorubicin-based chemotherapy, followed by allo-hematopoietic stem cell transplantation (HSCT) and IM maintenance regimen. Both patients obtained CHR and complete cytogenetic and molecular responses for 44 and 48 months.…”

Section: Discussionmentioning

confidence: 99%

“…Both patients obtained CHR and complete cytogenetic and molecular responses for 44 and 48 months. Another patient receiving unrelated allo-HSCT during CR2, and sustained CHR for 70 months (18); therefore, IM combined with chemotherapy, followed by allo-HSCT and IM maintenance treatment appears to be an effective treatment option for Ph + AML, particularly when IM is used early (17). …”

Section: Discussionmentioning

confidence: 99%

Philadelphia chromosome with acute myeloid leukemia and concurrent large B cell lymphoma of different origins: A case report

et al. 2017

View full text Add to dashboard Cite

Philadelphia chromosome with de novo acute myeloid leukemia (Ph + AML) arising from t(9;22) is an uncommon occurrence. Ph + AML is known to respond poorly to conventional chemotherapy. To the best of our knowledge, simultaneous diagnosis of de novo Ph + AML and lymphoma in a single patient has not yet been reported. The present study reports the case of a 37-year-old female patient who presented with bone pain, fever and lymphadenopathy, and was diagnosed as Ph + AML with concurrent diffuse large B cell lymphoma. Combined chemotherapy regimen covering AML and lymphoma was administered, achieving short-term response. However, the therapy soon failed and the patient succumbed to the disease. The present study reports the first case of Ph + AML occurring concurrently with diffuse large B cell lymphoma, and discusses certain differences between Ph + AML and chronic myelogenous leukemia in the myeloid blast crisis phase, as well as the appropriate therapeutic modalities for Ph + AML. In addition, the potential association between Ph + AML and diffuse large B cell lymphoma in this patient was investigated.

show abstract

“…Several case reports demonstrating the efficacy of tyrosine kinase inhibitors like imatinib and dasatinib towards BCR-ABL1 + AML [3,11,12,13,14,15] have been published, but there is only one report on nilotinib [16]. …”

Section: Discussionmentioning

confidence: 99%

BCR-ABL1+ Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1- Subclone as a Cause of Refractory Disease with Nilotinib Treatment

Neuendorff¹,

Schwarz²,

Hemmati³

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

The presence of a Philadelphia chromosome with a corresponding BCR-ABL1 rearrangement is the hallmark of chronic myeloid leukemia, but is considered a very rare event in de novo acute myeloid leukemia (AML). Here, we report the first case in which a dominant Philadelphia chromosome-positive subclone was detected upon relapse in a formerly Philadelphia chromosome-negative MLL-AF6⁺ AML. Due to refractory disease under salvage chemotherapy, the patient was started on nilotinib treatment. As a result, the Philadelphia chromosome-positive subclone was eradicated within 1 month; however, disease progressed and was again dominated by the Philadelphia chromosome-negative founding clone, demonstrating rapid clonal expansion under nilotinib-induced selection pressure. © 2014 S. Karger AG, Basel

show abstract

Prolonged Survival with Imatinib Mesylate Combined with Chemotherapy and Allogeneic Stem Cell Transplantation in de novo Ph+ Acute Myeloid Leukemia

Cited by 14 publications

References 25 publications

Rare but authentic Philadelphia-positive acute myeloblastic leukemia

Rare but authentic Philadelphia-positive acute myeloblastic leukemia

Philadelphia chromosome with acute myeloid leukemia and concurrent large B cell lymphoma of different origins: A case report

<b><i>BCR-ABL1</i></b><sup><i>+</i></sup> Acute Myeloid Leukemia: Clonal Selection of a <b><i>BCR-ABL1</i></b><sup><i>-</i></sup> Subclone as a Cause of Refractory Disease with Nilotinib Treatment

Contact Info

Product

Resources

About